...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Endocrine journal >Efficacy of Combined Treatment with Raloxifene and Alfacalcidol on Bone Density and Biochemical Markers of Bone Turnover in Postmenopausal Osteoporosis
【24h】

Efficacy of Combined Treatment with Raloxifene and Alfacalcidol on Bone Density and Biochemical Markers of Bone Turnover in Postmenopausal Osteoporosis

机译：雷洛昔芬和阿法骨化醇联合治疗对绝经后骨质疏松症骨密度和骨转换生化指标的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Because both raloxifene (RLX) and alfacalcidol (ALF) have been established as therapeutic agents for osteoporosis, it is tempting to speculate that the combination therapy of RLX and ALF might provide benefits over that of either one alone. However, the efficacy of the combination therapy has not been reported yet. The purpose of this study was thus to assess the efficacy of the combination therapy on bone mineral density (BMD) and bone turnover in patients with postmenopausal osteoporosis. Sixty postmenopausal patients (mean age 71.62 ± 9.9 years) with untreated osteoporosis were selected for this study, and were randomly divided into two groups by therapeutic regimen. Group A consisted of 28 patients treated with RLX plus ALF, while Group B consisted of 32 patients with RLX alone. Among them, 20 in group A and 22 in group B completed this study. Contrary to our expectations, at either 6 months or 12 months after the initiation of treatment, RLX plus ALF did not increase BMD at any of the skeletal sites measured, including lumbar spine, femur, and radius, nor did it reduce bone-specific alkaline phosphatase or N-terminal telopeptide of type I collagen more than RLX alone. Our results do not support the hypothesis that the combination therapy of RLX and ALF exerts more beneficial effects on bone compared than with RLX alone. However, it still remains unclear from this study whether the combination therapy of RLX and ALF is more efficacious in preventing fractures compared with RLX alone. Further studies are needed to clarify these issues.
机译：由于雷洛昔芬（RLX）和阿法骨化醇（ALF）已被确定为骨质疏松症的治疗剂，因此很容易推测，RLX和ALF的联合治疗可能比任何一种单独治疗都具有益处。然而，尚未报道联合疗法的功效。因此，本研究的目的是评估联合治疗对绝经后骨质疏松症患者骨矿物质密度（BMD）和骨转换的功效。本研究选择了60例绝经后骨质疏松症的绝经后患者（平均年龄71.62±9.9岁），并根据治疗方案随机分为两组。 A组由28例接受RLX加ALF治疗的患者组成，而B组由32例仅由RLX治疗的患者组成。其中，A组20人，B组22人完成了本研究。与我们的预期相反，在开始治疗后的6个月或12个月，RLX加ALF并未在所测量的任何骨骼部位（包括腰椎，股骨和radius骨）增加BMD，也没有降低骨骼特异性碱I型胶原蛋白的磷酸酶或N端端肽比单独的RLX多。我们的结果不支持以下假设：与单独使用RLX相比，RLX和ALF的联合治疗对骨骼产生更有益的作用。但是，从这项研究中仍然不清楚，与单独使用RLX相比，RLX和ALF的联合治疗在预防骨折方面是否更有效。需要进一步研究来澄清这些问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号